NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
Clinical Trials
11 trialsNCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT00126594 2016-09-16
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00796757 2015-05-27
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Hoffmann-La Roche
Phase 2 Completed
NCT01274273 2014-12-02
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
University of Aarhus
Phase 2 Unknown
NCT00520403 2014-10-13
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00059813 2013-08-26
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00873236 2013-08-12
MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00098618 2013-07-02
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00619268 2013-02-15
TORAVA
Centre Leon Berard
Phase 2 Completed
NCT00561912 2011-12-26
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated